Aurora reaffirms cannabis growth outlook

• Aurora Cannabis reaffirmed fiscal 2027 Q2 guidance for sequential revenue and adjusted EBITDA growth.
• The company expects recent acquisitions to contribute additional revenue and production capacity.
• Aurora reported $149 million in cash and no debt as of June 30, 2026.

Aurora Cannabis (NASDAQ:ACB) reaffirmed its fiscal 2027 second-quarter outlook for sequential growth in quarterly net revenue and adjusted EBITDA, supported by acquisitions and international medical cannabis operations.

The company said the acquisition of Safari Flower Company, which received EU-GMP certification in July, is expected to add incremental revenue and adjusted EBITDA while expanding production capacity for regulated European markets.

Aurora said it continues to see profitable performance in Germany and Poland, including holding the No. 1 market share position by revenue in Poland, while expanding its UK presence through the acquisitions of Internode Pharma and HAP Pharma Limited.

Aurora reported $149 million in cash as of June 30, 2026, with no debt, and said it plans continued investment in international markets to support long-term medical cannabis growth.

Aurora Cannabis produces and distributes medical cannabis products across international markets, with operations focused on regulated healthcare channels.

The company has expanded through acquisitions and international partnerships aimed at increasing production capacity and access to medical cannabis markets.